Literature DB >> 11320950

Stature as a prognostic factor in cystic fibrosis survival.

L T Beker1, E Russek-Cohen, R J Fink.   

Abstract

OBJECTIVE/
DESIGN: This study provides a longitudinal analysis of the National Cystic Fibrosis Patient Registry to determine if height-for-age percentile would be a useful predictor of survival.
SUBJECTS: All patients were selected from the national registry (n = 19,000) maintained by the Cystic Fibrosis Foundation's 115 accredited Cystic Fibrosis Care Centers in the United States. Inclusion in our analysis required that subjects were born between 1980 and 1989; had a minimum of 4 records each; the subject was alive at age 7; and the subject had a recorded height measurement at age 7 to 8 (n = 2,773). STATISTICAL ANALYSIS: The Cox proportional hazards model was used to compare height-for-age with survival. We recorded whether a subject was less than the 5th National Center for Health Statistics (NCHS) percentile at age 5 and then in a separate analysis at age 7. Cohort effect was coded as "1" if they were born before 1982 and "0" otherwise.
RESULTS: Stature is a significant prognostic indicator of survival. The relative hazard associated with height below the 5th NCHS percentile for age was significant for both males and females. In males at age 5 the relative hazard was 2.9, [95% confidence interval (CI) 1.23, 6.91; P < .02] and at age 7 it was 6.3 (95% CI 2.1, 18.8; P < .001). The relative hazard in females at age 5 was 4.3 (95% CI 2.4, 7.3; P < .0001) and at age 7 was 5.8 (95% CI 2.5, 13.1; P < .0001). APPLICATION: These highly significant relative hazard values strongly suggest that shorter patients are much more likely to die before taller patients. The dietetic professional should consider using height-for-age as an effective screening tool to identify patients at risk. Based on these data, short stature should not be considered benign to patients with cystic fibrosis. The CF team, clinicians, family, and patients need work together to maximize linear growth through medical and nutritional intervention.

Entities:  

Mesh:

Year:  2001        PMID: 11320950     DOI: 10.1016/S0002-8223(01)00113-4

Source DB:  PubMed          Journal:  J Am Diet Assoc        ISSN: 0002-8223


  29 in total

1.  Growth in Prepubertal Children With Cystic Fibrosis Treated With Ivacaftor.

Authors:  Michael S Stalvey; Jesse Pace; Minoo Niknian; Mark N Higgins; Valerie Tarn; Joy Davis; Sonya L Heltshe; Steven M Rowe
Journal:  Pediatrics       Date:  2017-02       Impact factor: 7.124

Review 2.  Advancing outcome measures for the new era of drug development in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Bonnie W Ramsey; Richard A Kronmal
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

3.  Growth and pulmonary outcomes during the first 2 y of life of breastfed and formula-fed infants diagnosed with cystic fibrosis through the Wisconsin Routine Newborn Screening Program.

Authors:  Sarah A Jadin; Grace S Wu; Zhumin Zhang; Suzanne M Shoff; Benjamin M Tippets; Philip M Farrell; Tami Miller; Michael J Rock; Hara Levy; HuiChuan J Lai
Journal:  Am J Clin Nutr       Date:  2011-03-23       Impact factor: 7.045

4.  Pubertal Height Growth and Adult Height in Cystic Fibrosis After Newborn Screening.

Authors:  Zhumin Zhang; Mary J Lindstrom; Philip M Farrell; HuiChuan J Lai
Journal:  Pediatrics       Date:  2016-04-05       Impact factor: 7.124

Review 5.  Impact of vitamin D on infectious disease.

Authors:  Malcolm D Kearns; Jessica A Alvarez; Natan Seidel; Vin Tangpricha
Journal:  Am J Med Sci       Date:  2015-03       Impact factor: 2.378

6.  Administration of CREON® pancrelipase pellets via gastrostomy tube is feasible with no loss of gastric resistance or lipase activity: an in vitro study.

Authors:  George Shlieout; Andreas Koerner; Mario Maffert; Kristin Forssmann; Steven Caras
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

7.  A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis.

Authors:  Michael S Stalvey; Ran D Anbar; Michael W Konstan; Joan R Jacobs; Bert Bakker; Barbara Lippe; David E Geller
Journal:  Pediatr Pulmonol       Date:  2011-09-08

8.  Recovery of birth weight z score within 2 years of diagnosis is positively associated with pulmonary status at 6 years of age in children with cystic fibrosis.

Authors:  Huichuan J Lai; Suzanne M Shoff; Philip M Farrell
Journal:  Pediatrics       Date:  2009-02       Impact factor: 7.124

9.  Vitamin d deficiency in cystic fibrosis.

Authors:  William B Hall; Amy A Sparks; Robert M Aris
Journal:  Int J Endocrinol       Date:  2010-01-28       Impact factor: 3.257

10.  Oxandrolone Improves Height Velocity and BMI in Patients with Cystic Fibrosis.

Authors:  Todd Varness; Erin E Seffrood; Ellen L Connor; Michael J Rock; David B Allen
Journal:  Int J Pediatr Endocrinol       Date:  2010-01-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.